<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653223</url>
  </required_header>
  <id_info>
    <org_study_id>statin2</org_study_id>
    <secondary_id>5010-2012001</secondary_id>
    <secondary_id>5010-2014002</secondary_id>
    <nct_id>NCT01653223</nct_id>
  </id_info>
  <brief_title>Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery</brief_title>
  <official_title>A Study of Simvastatin on Myocardial Protection and Cardiac Function Undergoing Cardiac Surgery With Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins have been used to low cholesterol to prevent and treat coronary artery diseases. It&#xD;
      was also reported that statins could protect endothelial function and cardiac function during&#xD;
      coronary artery bypass graft. The investigators recent found simvastatin reduced myocardial&#xD;
      injury during noncoronary artery cardiac surgery in single medical center. The investigators&#xD;
      further investigate that whether simvastatin can protect myocardium during noncoronary artery&#xD;
      cardiac surgery with cardiopulmonary bypass and improve cardiac function with long term use&#xD;
      postoperatively in two medical centers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>troponin</measure>
    <time_frame>within the first 7 days after surgery</time_frame>
    <description>The investigator will measure the plasma troponin level in several time points before and after surgery in each patient. This is mainly for the comparason between control and short statin, which has been proved in our previous clinical trial: statin1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ejection fraction</measure>
    <time_frame>within two years</time_frame>
    <description>Each patient will be followed up and checked with B ultrasound on heart in 1,3,6,12,18 and 24 months after surgery. The ejection fraction will be measured. This is mainly for the comparason between short statin and long statin, which is the major goal in this clinical trial: statin 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>long term survival</measure>
    <time_frame>within two years</time_frame>
    <description>Each patient will be followed up and observed survival time.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>untreated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>short statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 7 days postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>long statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 6 months postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.&#xD;
In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months.</description>
    <arm_group_label>long statin</arm_group_label>
    <arm_group_label>short statin</arm_group_label>
    <other_name>simcor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than 18-year-old,&#xD;
&#xD;
          -  Congenital heart disease(not complex),&#xD;
&#xD;
          -  Isolated heart valve disease,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coronary artery disease&#xD;
&#xD;
          -  Allergy for statins&#xD;
&#xD;
          -  Poor liver function,Hepatitis&#xD;
&#xD;
          -  Gestation women and Breast-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing-song Ou, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Frist Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing-song Ou, MD, PhD</last_name>
    <phone>8620-87755766</phone>
    <phone_ext>8238</phone_ext>
    <email>oujs2000@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi-ping Wang, MD, PhD</last_name>
    <phone>8620-87755766</phone>
    <phone_ext>8238</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cong-zhi Rao, MD</last_name>
      <phone>87333122</phone>
      <email>raoczh@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jing-song Ou, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 26, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>December 5, 2020</last_update_submitted>
  <last_update_submitted_qc>December 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jing-song Ou</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

